×
About 46,343 results

ALLMedicine™ Psoriasis Center

Research & Reviews  12,544 results

Exploration of Biomarkers of Psoriasis through Combined Multiomics Analysis.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525798
Mediators of Inflammation; Xing L, Wu T et. al.

Oct 5th, 2022 - Aberrant DNA methylation patterns are of increasing interest in the study of psoriasis mechanisms. This study aims to screen potential diagnostic indicators affected by DNA methylation for psoriasis based on bioinformatics using multiple machine l...

Veganism in acne, atopic dermatitis, and psoriasis: benefits of a plant-based diet.
https://doi.org/10.1016/j.clindermatol.2022.09.008
Clinics in Dermatology; Marta F

Oct 4th, 2022 - Plant-based diets and veganism are receiving increased attention for many reasons. Leading international nutrition organizations have determined that a well-planned and balanced plant-based diet is protective against such chronic diseases as obesi...

Dermcidin-derived polypeptides: DCD(86-103) induced inflammatory reaction in the skin b...
https://doi.org/10.1016/j.imlet.2022.09.008
Immunology Letters; Che D, Jia T et. al.

Oct 4th, 2022 - Psoriasis is a chronic inflammatory disease. Mast cells are significantly increased and activated in the lesions of patients with psoriasis, contributing to psoriatic inflammation. Dermcidin (DCD) is a natural antibacterial peptide secreted by swe...

The search for measurable predictors linked with negative health complications in psori...
https://doi.org/10.1111/bjd.21799
The British Journal of Dermatology;

Oct 4th, 2022 - The search for measurable predictors linked with negative health complications in psoriasis.|2022||

The length of stay and inpatient burden in inpatients with different psoriasis subtypes.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515696
International Journal of Medical Sciences; Wang Q, Jin L et. al.

Oct 4th, 2022 - Background: Heavy disease burden of psoriasis has been indicated by previous studies. However, the cost of care and length of stay (LOS) in inpatients with different psoriasis subtypes were rarely addressed. This study aimed to investigate the cos...

see more →

Guidelines  24 results

FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older
https://www.arcutis.com/fda-approves-arcutis-zoryve-roflumilast-cream-0-3-for-the-treatment-of-plaque-psoriasis-in-individuals-age-12-and-older/
Arcutis Biotherapeutics, Inc.

Jul 29th, 2022 - WESTLAKE VILLAGE, Calif., July 29, 2022 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, announced today that t...

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specifi...
https://doi.org/10.1111/jdv.16926
Journal of the European Academy of Dermatology and Venere... Nast A, Smith C et. al.

Feb 7th, 2021 - This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The second part of the guideline provides guidance for specific clini...

National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788316
Journal of the American Academy of Dermatology; Gelfand JM, Armstrong AW et. al.

Jan 11th, 2021 - To update guidance regarding the management of psoriatic disease during the COVID-19 pandemic. The task force (TF) includes 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical ca...

Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway.
https://doi.org/10.1159/000512930
Dermatology (Basel, Switzerland); Maul JT, Anzengruber F et. al.

Jan 7th, 2021 - Topical treatment is crucial for the successful management of plaque psoriasis. Topicals are used either as a stand-alone therapy for mild psoriasis or else in combination with UV or systemic treatment for moderate-to-severe disease. For the choic...

Portuguese recommendations for the treatment of psoriasis with biologic therapy.
https://doi.org/10.1684/ejd.2020.3945
European Journal of Dermatology : EJD; Torres T, Tavares Bello R et. al.

Dec 11th, 2020 - Psoriasis is a highly prevalent chronic, inflammatory multisystem disease with a considerable impact on patients' quality of life and the healthcare system. This report presents the recommendations developed by the Portuguese Psoriasis Group of th...

see more →

Drugs  999 results see all →

Clinicaltrials.gov  1,734 results

A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice
https://clinicaltrials.gov/ct2/show/NCT04053881

Sep 30th, 2022 - The purpose of the study is to assess the effectiveness of certolizumab pegol in patients with moderate to severe plaque psoriasis as part of routine clinical practice.

Brain Changes in Psoriasis After Secukinumab Treatment
https://clinicaltrials.gov/ct2/show/NCT04717466

Sep 30th, 2022 - The purpose of this study is to assess the effect of a biologic drug targeting the Interleukin (IL)-17 pathway (secukinumab) on brain plasticity and examine whether the plastic changes correlate with the improvement of perception of well-being, it...

Multi-Center PAMPA Study
https://clinicaltrials.gov/ct2/show/NCT05004727

Sep 30th, 2022 - This is a multi-center (North-America), randomized, double-blind, placebo-controlled, wait-list, interventional, preventive trial of guselkumab in high-risk psoriasis patients compared to non-biologic standard of care. The primary objective of our...

Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis
https://clinicaltrials.gov/ct2/show/NCT04128007

Sep 30th, 2022 - This is a parallel group, double blind, vehicle-controlled study in which ARQ-154 foam or vehicle is applied once daily x 8 weeks to adolescent and adult subjects with scalp and body psoriasis

Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)
https://clinicaltrials.gov/ct2/show/NCT04053387

Sep 29th, 2022 - At the completion of the Week-12 visit of the pivotal study (Baseline [Day 1] in this study), all eligible subjects will be offered enrollment in the long-term extension study. Study visits during the treatment period for all subjects will occur e...

see more →

News  3,190 results

Commentary: Disease Activity, Progression to Psoriasis, and More in PsA, October 2022
https://www.mdedge.com/rheumatology/article/258289/psoriatic-arthritis/commentary-disease-activity-progression-psoriasis
Vinod Chandran, MBBS, MD, DM, PhD

Sep 29th, 2022 - Vinod Chandran, MBBS, MD, DM, PhD Research on psoriatic arthritis (PsA) published over the past month has highlighted the effect of disease on patients and provided insights into clinical management. Because of the heterogeneous nature of PsA, ass.

Apremilast May Have Some Cardiometabolic Benefits in Patients With Psoriasis
https://www.medscape.com/viewarticle/981484

Sep 27th, 2022 - Apremilast may have an overall benefit for patients with cardiometabolic disease and psoriasis, new results from a nonrandomized clinical trial suggest. The trial, led by Joel M. Gelfand, MD, MSCE, professor of dermatology and epidemiology and vic...

Psoriasis, PsA Insurance Coverage Remains Restrictive
https://www.medscape.com/viewarticle/981532

Sep 27th, 2022 - Insurance coverage for specialty drugs to treat psoriasis and psoriatic arthritis varies extensively among insurance companies and often restricts coverage beyond the drug labels, according to a review of data from commercial health plans in the U...

Psoriasis, psoriatic arthritis insurance coverage remains restrictive
https://www.mdedge.com/rheumatology/article/258217/psoriatic-arthritis/psoriasis-psoriatic-arthritis-insurance-coverage
Heidi Splete

Sep 26th, 2022 - Insurance coverage for specialty drugs to treat psoriasis and psoriatic arthritis varies extensively among insurance companies and often restricts coverage beyond the drug labels, according to a review of data from commercial health plans in the U.

Scalp plaque
https://www.mdedge.com/familymedicine/article/258145/dermatology/scalp-plaque
MDedge Family Medicine;

Sep 22nd, 2022 - A punch biopsy was performed, and the results were consistent with pityriasis amiantacea arising from psoriasis. In an older patient, a keratinaceous horn would be worrisome for a squamous cell carcinoma.

see more →

Patient Education  46 results see all →